Long-term Follow-up of Hemostatic Molecular Markers during Remission Induction Therapy with All-Trans Retinoic Acid for Acute Promyelocytic Leukemia

Summary

Hemostatic molecular markers were serially monitored in a prospective fashion during remission induction therapy with all-trans retinoic acid (ATRA) in sixteen patients with acute promyelocytic leukemia (APL). One patient with leukocytosis before treatment and three patients who later developed hyperleukocytosis also received chemotherapy with behenoyl Ara-C and daunorubicin. Plasma levels of E-fragment of fibrin and fibrinogen degradation product (FDP-E), FDP-D dimer (D-D), thrombin-antithrombin complex (TAT), and plasmin-α₂ plasmin inhibitor complex (PIC) were markedly elevated in all but one patient before treatment, and these parameters decreased to normal or near normal ranges in most patients within the first 7 days of treatment. Interestingly, we have found that these parameters were again elevated during the later course of ATRA therapy (after day +7) in eleven patients for various reasons including cytotoxic chemotherapy (3 cases), fever (5 cases; 2 cases with apparent infection, 3 cases without known etiology), Caesarean section (1 case), and no apparent etiology (2 cases). Three patients showed bleeding complications during reelevation of molecular markers, but none developed thrombosis. Plasma elastase-α₁ proteinase inhibitor complex (E-α₁PI) was markedly elevated in all patients at diagnosis and did not decrease significantly during ATRA therapy. Plasma tissue factor antigen was mildly elevated in one out of four patients studied, and thrombomodulin was elevated in two out of ten patients tested. These results confirmed the rapid normalization of coagulopathy during the early phase of remission induction therapy with ATRA but suggest that re-elevation of molecular markers occurs frequently during the later course of ATRA therapy.

• References

• 1 Andoh K, Kubota T, Takeda M, Tanaka H, Kobayashi N, Maekawa T. Tissue factor activity in leukemia cells. Cancer 1987; 59: 748-754
• 2 Gouault-Heilmann M, Chardon E, Sultan C, Josso F. The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 1975; 30: 151-158
• 3 Imaoka S, Ueda T, Shibata H, Masaoka T, Ogawa M, Sasaki Y, Iwanaga T, Terasawa T. Fibrinolysis in patients with acute promyelocytic leukemia and disseminated intravascular coagulation during heparin therapy. Cancer 1986; 58: 1736-1738
• 4 Sterrenberg L, Haak HL, Brommer EJP, Nieuwenhuizen W. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985; 15: 126-133
• 5 Wijermans PW, Rebel VI, Ossenkoppele GJ, Huijgens PC, Langenhuijsen MMAC. Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of bleeding disorder by cell differentiation. Blood 1989; 73: 800-805
• 6 Guarini A, Gugliotta L, Catani L, Chetti L, Macchi S, Tura S. Procoagulant cellular activity (PCA) in the classification of acute leukemia. Thromb Res 1987; 45: 545-552
• 7 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-2117
• 8 Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-553
• 9 Warrell Jr RP, The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Eng J Med 1993; 329: 177-189
• 10 Bassan R, Battista R, Viero P, d’Emilio A, Buelli M, Montaldi A, Rambaldi A, Tremul L, Dini E, Barbui T. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 1995; 9: 238-243
• 11 Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of al1-taws retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572
• 12 Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-transretinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 1990; 76: 1704-1709
• 13 Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu WY, Yao XZ, Ling BJ. A clinical and experimental study on all-transretinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419
• 14 Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinon (all-transretinoic acid). N Eng J Med 1991; 324: 1385-1393
• 15 Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, Degos L. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-transretinoic acid treatment. Leukemia 1993; 07: 2-9
• 16 Kawai Y, Watanabe K, Kizaki M, Murata M, Kamata T, Uchida H, Moriki T, Yokoyama K, Tokuhira M, Nakajima H, Handa M, Ikeda Y. Rapid improvement of coagulopathy by all-taws retiiloic acid in acute promyelocytic leukemia. Am J Hematol 1994; 46: 184-188
• 17 Falanga A, Iacoviello L, Evangelista V, Belotti D, Consonni R, D’Orazio A, Robba L, Donati MB, Barbui T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patient with acute promyelocytic leukemia administered all-transretinoic acid. Blood 1995; 86: 1072-1081
• 18 Nakamura S, Kamikubo Y, Okajima K, Asakura H, Nakamura K. Plasma tissue factor: its sensitive assay and characterization. Thromb Haemost 1993; 69: 744 (abstr).
• 19 Watanabe R, Okamoto S, Moriki T, Kizaki M, Kawai Y, Ikeda Y. Treatment of acute promyelocytic leukemia with all-taws retinoic acid during the third trimester of pregnancy. Am H Hematol 1995; 48: 210-211
• 20 Falanga A, Consonni R, Marchetti M, Mielicki WP, Rambaldi A, Lanotte M, Gordon SG, Barbui T. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-transretinoic acid. Leukemia 1994; 08: 156-159
• 21 Stefano VD, Teofili L, Sica S, Mastrangelo S, Mario AD, Rutella S, Salutari P, Rumi C, d’Onofrio G, Leone G. Effect of all-taws retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995; 86: 3535-3541
• 22 Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-taws retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994; 84: 3001-3009
• 23 Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood 1994; 83: 1883-1891
• 24 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-taws retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocyte leukemia-derived cell line (NB4). Blood 1996; 87: 613-617
• 25 Saito T, Koyama T, Nagata K, Kamiyama R, Hirosawa S. Anticoagulant effects of retinoic acids on leukemia cells. Blood 1996; 87: 657-665
• 26 Kramps JA, Valk PVD, Sandt MMVD, Lindeman J, Meijer CJLM. Elastase as a marker for neutrophilic myeloid cells. J Histochem Cytochem 1994; 32: 389-394
• 27 Galloway MJ, Mackie MJ, McVerry BA. Elastase-eq antitrypsin complexes in acute leukaemia. Thromb Res 1985; 38: 311-320
• 28 Firkin F, Cannell P, McDonald A, Hughes T, Gill D, Lowenthal R, Seldon M, Wiley J. Recurrence of life-threatening DIC during all-transretinoic acid (ATRA) therapy of acute promyelocytic (APML). Blood 1995; 86 (10) (Suppl. 01) 172a (abstract).